# Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma

> **NCT00216437** · PHASE1 · TERMINATED · sponsor: **James A. Haley Veterans Administration Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Cancer of Liver

## Interventions

- **DRUG:** Capecitabine (Xeloda)

## Key facts

- **NCT ID:** NCT00216437
- **Lead sponsor:** James A. Haley Veterans Administration Hospital
- **Sponsor class:** FED
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-12
- **Primary completion:** —
- **Final completion:** 2007-03
- **Target enrollment:** 30 (ESTIMATED)
- **Why stopped:** lack of accrual
- **Last updated:** 2007-11-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216437, "Dose Escalation Study Combining Oral Capecitabine (Xeloda) and Radiotherapy for Patients With Unresectable Liver or Cholangiocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00216437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*